Form 4: Janux Therapeutics CEO Sells 15,000 Shares Under 10b5-1 Trading Plan

Janux Therapeutics CEO, David Alan Campbell, sold 15,000 shares of common stock at $67 per share on December 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• David Alan Campbell, the President and CEO of Janux Therapeutics, sold 15,000 shares of the company's common stock on December 3, 2024.
• The sale was executed at a price of $67 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 21, 2024.
• Following the sale, Mr. Campbell directly owns 242,054 shares of Janux Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's prospects. It is a neutral event.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a common practice in the biotech industry, similar to companies like Amgen, Regeneron, and Gilead Sciences, where executives often have pre-arranged trading plans.
• The size of the sale, 15,000 shares, is not unusual for an executive of a company of Janux's size and market capitalization.
• The price of $67 per share is reflective of the current market valuation of the company's stock at the time of the transaction.

Stakeholder Impact

• The sale may have a minor impact on the stock price, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Janux Therapeutics, David Alan Campbell, insider trading, stock sale, Rule 10b5-1, executive, share transaction